Exact Sciences is charting big plans for 2015, increasing its sales efforts and pushing for expanded coverage of its stool-based DNA colon cancer test to grab a bigger market share.
23andMe nabbed FDA clearance to market its genetic carrier test directly to consumers, a big win for the company as it continues to get back in the agency's good graces and expand the reach for its genetic tests. Read more >>
Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression. Read more >>
POPULAR COMMENT THREADS
Navidea Biopharmaceuticals is teaming up with European specialty pharma company Norgine to commercialize its Lymphoseek cancer diagnostic aid in Europe, looking to make a market splash as it drives international growth.
Microbial genetics analysis outfit OpGen is inching one step closer to an initial public offering, planning to raise up to $37 million for its genetic screening technologies for drug-resistant bacteria.
"This thing isn't over yet," warned President Barack Obama's Ebola czar Ron Klain in a recent interview. While recovering slowly West Africa is plagued by the epidemic and needs new tools in the ongoing battle against the disease.
Illumina's new business accelerator, Illumina Accelerator Boost Capital, got a $40 million cash infusion from hedge fund Viking Global Investors. Illumina Accelerator will use the cash to fund investments in promising genomic startups, spurring innovation and providing dollar-for-dollar matching funds for every graduate company that raises between $1 million and $5 million during the funding cycle.
Researchers have discovered that a skin sample taken from behind the ear of patients with either Alzheimer's or Parkinson's disease had levels of the protein tau 7 times higher than those without the condition. Those with Parkinson's showed levels of alpha-synuclein protein that were 8 times higher than those in the control group.
From Our Sister Sites
Merck has pulled the plug on Cubist Pharmaceuticals' early R&D operation, cutting 120 jobs in Massachusetts as it integrates its latest big acquisition.
Milan-based Genenta Science has raised $11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.